NAKA vs. TOI, LFMD, VMD, XGN, CORBF, DCGO, BNR, QIPT, EUDA, and SERA
Should you be buying KindlyMD stock or one of its competitors? The main competitors of KindlyMD include Oncology Institute (TOI), LifeMD (LFMD), Viemed Healthcare (VMD), Exagen (XGN), Global Cord Blood (CORBF), DocGo (DCGO), Burning Rock Biotech (BNR), Quipt Home Medical (QIPT), EUDA Health (EUDA), and Sera Prognostics (SERA). These companies are all part of the "healthcare" industry.
KindlyMD vs. Its Competitors
KindlyMD (NASDAQ:NAKA) and Oncology Institute (NASDAQ:TOI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.
Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 100.57%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than KindlyMD.
In the previous week, Oncology Institute had 1 more articles in the media than KindlyMD. MarketBeat recorded 3 mentions for Oncology Institute and 2 mentions for KindlyMD. Oncology Institute's average media sentiment score of 0.88 beat KindlyMD's score of 0.09 indicating that Oncology Institute is being referred to more favorably in the news media.
36.9% of Oncology Institute shares are owned by institutional investors. 40.8% of KindlyMD shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
KindlyMD has a beta of 34.35, suggesting that its share price is 3,335% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
KindlyMD has higher earnings, but lower revenue than Oncology Institute. KindlyMD is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute has a net margin of -14.26% compared to KindlyMD's net margin of -244.00%. KindlyMD's return on equity of -131.09% beat Oncology Institute's return on equity.
Summary
Oncology Institute beats KindlyMD on 12 of the 17 factors compared between the two stocks.
Get KindlyMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KindlyMD Competitors List
Related Companies and Tools
This page (NASDAQ:NAKA) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access